Effect of AZD9977 and spironolactone on serum potassium in heart failure with preserved or mildly reduced ejection fraction, and renal impairment: A randomized trial-Reference-Cited by-同舟云学术

Effect of AZD9977 and spironolactone on serum potassium in heart failure with preserved or mildly reduced ejection fraction, and renal impairment: A randomized trial

Published:2022-08-20 Issue:10 Volume:15 Page:2493-2504
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clinical Translational Sci

Author:

Squire Iain B.¹²,Gabrielsen Anders³,Greasley Peter J.³^ORCID,Wernevik Linda³,Hartleib‐Geschwindner Judith⁴,Holden Julie⁵,Johansson Susanne³,Rudvik Anna⁶,Sánchez José⁶,Bamberg Krister⁷,Melin Johanna⁸,Whittaker Andrew⁹

Affiliation:

1. NIHR Biomedical Research Centre Glenfield Hospital Leicester UK

2. Department of Cardiovascular Sciences University of Leicester Leicester UK

3. Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism BioPharmaceuticals R&D, AstraZeneca Gothenburg Sweden

4. Late‐stage Development, Cardiovascular, Renal, and Metabolism BioPharmaceuticals R&D, AstraZeneca Gothenburg Sweden

5. Global Drug Safety, Oncology R&D AstraZeneca Gaithersburg Maryland USA

6. Early Biometrics and Statistical Innovation, Data Science and AI BioPharmaceuticals R&D, AstraZeneca Gothenburg Sweden

7. Translational Sciences and Experimental Medicines, Research and Early Development, Cardiovascular, Renal and Metabolism BioPharmaceuticals R&D, AstraZeneca Gothenburg Sweden

8. Clinical & Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences R&D, AstraZeneca Gothenburg Sweden

9. Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism BioPharmaceuticals R&D, AstraZeneca Cambridge UK

Funder

AstraZeneca

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.13377

Reference23 articles.

1. Global Public Health Burden of Heart Failure

2. Mineralocorticoid Receptor Signaling as a Therapeutic Target for Renal and Cardiac Fibrosis

3. Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease

4. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

5. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Can the novel aldosterone inhibiting drug balcinrenone reduce hyperkalaemia and worsening renal function compared to steroidal mineralocorticoid receptor antagonists in heart failure?;European Journal of Heart Failure;2024-07-22

2. Aldosterone and Aldosterone Synthase Inhibitors in Cardiorenal Disease;American Journal of Physiology-Heart and Circulatory Physiology;2023-12-22

3. Molecular pharmacology of mineralocorticoid receptor antagonists: The role of co-regulators;Steroids;2023-11

4. Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA);Clinical Kidney Journal;2023-06-24